2. Search Result
Search Result
Results for "

Aortic ring

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

7

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W005255
    3-(3-Hydroxyphenyl)propionic acid

    		Endogenous Metabolite Cardiovascular Disease
    3-(3-Hydroxyphenyl)propionic acid is a flavonoid metabolite formed by human microflora. 3-(3-Hydroxyphenyl)propionic acid shows vasodilatory activity .
    3-(3-Hydroxyphenyl)propionic acid
  • HY-103291
    Sar-[D-Phe8]-des-Arg9-Bradykinin

    		Bradykinin Receptor Inflammation/Immunology Endocrinology
    Sar-[D-Phe8]-des-Arg9-Bradykinin is a agonist of B1 receptor. Sar-[D-Phe8]-des-Arg9-Bradykinin selectively amplifies the contractile response when incubation with human recombinant interleukin-1 β (IL-1 β) in rabbit aortic rings .
    Sar-[D-Phe8]-des-Arg9-Bradykinin
  • HY-Y0337A
    L-Cysteine hydrochloride
    5+ Cited Publications

    		 Endogenous Metabolite Metabolic Disease Cancer
    L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) .
    L-Cysteine hydrochloride
  • HY-N9005
    Dysolenticin J

    		Others Cardiovascular Disease
    Dysolenticin J has potent vasodilative effects on aortic rings. Dysolenticin J is an alkaloid that can be isolated from Dysoxylum lenticellatum .
    Dysolenticin J
  • HY-129665
    GS-389

    (±)-O,O-Dimethylcoclaurine

    		 Endogenous Metabolite Metabolic Disease
    GS 389 ((±)-O,O-Dimethylcoclaurine) is a tetrahydroisoquinoline. GS-389 inhibites Cyclic AMP and cyclic AMP dependent phosphodiesterases from rat atrial and ventricular tissue. GS-389 relaxes the contraction induced by phenylephrine and high K + in rat aortic rings .
    GS-389
  • HY-N15186
    Gymnoascolide A

    		Fungal Cardiovascular Disease
    Gymnoascolide A, identified as a fungal metabolite in M. filamentosa, demonstrates vasodilatory effects. At a concentration of 1 µM, it effectively inhibits contractions induced by calcium in isolated rat aortic rings .
    Gymnoascolide A
  • HY-W005255R
    3-(3-Hydroxyphenyl)propionic acid (Standard)

    		Endogenous Metabolite Cardiovascular Disease
    Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
    3-(3-Hydroxyphenyl)propionic acid (Standard)
  • HY-W103372
    Vasorelaxant agent-2

    		Adrenergic Receptor Cardiovascular Disease
    Vasorelaxant agent-2 (Compound 8h) targets α1A-adrenergic receptor with an affinity of pD2=5.4. Vasorelaxant agent-2 exhibits vasodilator activity in rats aortic rings with an EC50 of 0.79 μM .
    Vasorelaxant agent-2
  • HY-117568
    A-80b

    		Calcium Channel Cardiovascular Disease
    A-80b is a pyridazino[4,5-b]indole derivate. A 80b showsantihypertensive activity and can be used for study of Arterial hypertension .
    A-80b
  • HY-161836
    α2AR agonist 1

    		Adrenergic Receptor Cardiovascular Disease
    α2AR agonist 1 (compound S6a), a new morpholine-containing pyrimidinone, acts as an agonist of α2-adrenoceptor. α2AR agonist 1 induces a concentration-dependent relaxation on aortic ring pre-contracted with Phenylephrine (HY-B0769; pEC50=6.81). α2AR agonist 1 increases NOx and NO levels in HUVECs .
    α2AR agonist 1
  • HY-105572
    Moveltipril calcium

    MC-838 calcium

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Moveltipril calcium (MC-838 calcium) is an orally active angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moveltipril calcium binds via a stable thioester bond and exhibits relative resistance to enzymatic hydrolysis in rat liver homogenate. Moveltipril calcium effectively inhibits ACE extracted from rabbit lung in a concentration-dependent manner. Moveltipril calcium is able to highly specifically inhibit the contractile response to angiotensin-I (AI) in free rat aortic rings and guinea pig ileum preparations, while enhancing the contractile response to calcitonin .
    Moveltipril calcium
  • HY-Y0337AR
    L-Cysteine (hydrochloride) (Standard)

    		Endogenous Metabolite Metabolic Disease Cancer
    L-Cysteine (hydrochloride) (Standard) is the analytical standard of L-Cysteine (hydrochloride). This product is intended for research and analytical applications. L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) [4].
    L-Cysteine (hydrochloride) (Standard)
  • HY-117991
    DW10075

    		VEGFR Cancer
    DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
    DW10075

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: